Background
The purpose of the current study was to investigate the predictive value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography (18F‐FDG PET/CT) for programmed death ligand 1 (PD‐L1) in non‐small cell lung cancer (NSCLC) patients through a systematic review and meta‐analysis.
Methods
The PubMed, Cochrane, and EMBASE database, from the earliest available date of indexing through 30 April 2020, were searched for studies evaluating the diagnostic performance of 18F‐FDG PET/CT for prediction of PD‐L1 expression in NSCLC patients.
Results
Across six studies (1739 patients), the pooled sensitivity for 18F‐FDG PET/CT was 0.72 (95% CI: 0.58–0.82) with heterogeneity (I
2
= 90.9,
P
< 0.001) and a pooled specificity of 0.69 (95% CI: 0.64–0.74) with heterogeneity (I
2
= 77.9,
P
< 0.001). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR +) of 2.3 (95% CI: 1.8–2.9) and negative likelihood ratio (LR‐) of 0.41 (95% CI: 0.26–0.63). The pooled diagnostic odds ratio (DOR) was six (95% CI: 3–11). Hierarchical summary receiver operating characteristic (ROC) curve indicated that the area under the curve was 0.74 (95% CI: 0.70–0.78).
Conclusions
The current meta‐analysis showed a moderate sensitivity and specificity of 18F‐FDG PET/CT for the prediction of PD‐L1 expression in NSCLC patients. The DOR was low and the likelihood ratio scatter‐gram indicated that 18F‐FDG PET/CT might not be useful for the prediction of PD‐L1 expression in NSCLC patients and not for its exclusion.
Key points
Significant findings of the study
The current meta‐analysis showed a moderate sensitivity and specificity of 18F‐FDG PET/CT for the prediction of PD‐L1 expression in NSCLC patients. The DOR was low and the likelihood ratio scattergram indicated that 18F‐FDG PET/CT might not be useful for the prediction of PD‐L1 expression in NSCLC patients and not for its exclusion.
What this study adds
This study concluded that the role of 18F‐FDG PET/CT in predicting tumor expression of PD‐L1 should be further elucidated.
Purpose:The aim of this study is to evaluate whether low FDG uptake would be associated with the biological lowaggressiveness of invasive ductal carcinoma. Methods: The subjects consisted of 124 female patients with primary invasive ductal carcinoma. All the patients were examined with 18 F-FDG PET/CT before neoadjuvant chemotherapy. Results: With regard to histopathologic grading, 117 were histopathologic grade 1 and 2, and 7 were grade 3. Low FDG uptake correlated with well and moderate histopathologic grade (p=0.003) and low 18 F-FDG uptake in invasive ductal carcinoma depended on the presence of axillary lymph node metastases (p=0.014) and small tumor (<2.0 cm, p=0.022). Ki-67 positivity ranged from 0% to 60% (mean 15%). Sixty seven specimens showed low immunoreactivity to antigen (<10% of tumor cells). This revealed a significant correlation between low FDG uptake and . Logistic regression analysis between these factors showed that lower histologic grade, no axillary lymph nodes metastases and low Ki-67 (<10%) were correlated with low FDG uptake. Conclusion: Our results demonstrated that an association exists between low FDG uptake and good prognostic factors such as lower histologic grade (1, 2), no axillary lymph node metastases and low Ki-67 (<10%).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.